» Articles » PMID: 31849997

Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases

Overview
Journal Front Immunol
Date 2019 Dec 19
PMID 31849997
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic macrophages play a central role in maintaining homeostasis in the liver, as well as in the initiation and progression of liver diseases. Hepatic macrophages are mainly derived from resident hepatic macrophages called Kupffer cells or circulating bone marrow-derived monocytes. Kupffer cells are self-renewing and typically non-migrating macrophages in the liver and are stationed in the liver sinusoids in contrast to macrophages originating from circulating monocytes. Kupffer cells regulate liver homeostasis by mediating immunity against non-pathogenic blood-borne molecules, while participating in coordinated immune responses leading to pathogen clearance, leukocyte recruitment and antigen presentation to lymphocytes present in the vasculature. Monocyte-derived macrophages infiltrate into the liver tissue when metabolic or toxic damage instigates and are likely dispensable for replenishing the macrophage population in homeostasis. In recent years, different populations of hepatic macrophages have been identified with distinct phenotypes with discrete functions, far beyond the central dogma of M1 and M2 macrophages. Hepatic macrophages play a central role in the pathogenesis of acute and chronic liver failure, liver fibrosis, non-alcoholic fatty liver disease, alcoholic liver disease, viral hepatitis, and hepatocellular carcinoma, as well as in disease resolution. The understanding of the role of hepatic macrophages in liver diseases provides opportunities for the development of targeted therapeutics for respective malignancies. This review will summarize the current knowledge of the hepatic macrophages, their origin, functions, their critical role in maintaining homeostasis and in the progression or resolution of liver diseases. Furthermore, we will provide a comprehensive overview of the therapeutic targeting strategies against hepatic macrophages developed for the treatment of liver diseases.

Citing Articles

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.

Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S J Inflamm Res. 2025; 18:883-894.

PMID: 39867947 PMC: 11760270. DOI: 10.2147/JIR.S498340.


Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.

Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F Biomolecules. 2025; 15(1).

PMID: 39858515 PMC: 11763965. DOI: 10.3390/biom15010121.


Innate immune cells link dietary cues to normal and abnormal metabolic regulation.

Zhang P, Watari K, Karin M Nat Immunol. 2025; 26(1):29-41.

PMID: 39747429 DOI: 10.1038/s41590-024-02037-y.


Metabolic Reprograming of Macrophages: A New Direction in Traditional Chinese Medicine for Treating Liver Failure.

Zhang J, Li N, Hu X J Immunol Res. 2025; 2024():5891381.

PMID: 39741958 PMC: 11688140. DOI: 10.1155/jimr/5891381.


Key role of macrophages in the progression of hepatic fibrosis.

Ran J, Yin S, Issa R, Zhao Q, Zhu G, Zhang H Hepatol Commun. 2024; 9(1).

PMID: 39670853 PMC: 11637753. DOI: 10.1097/HC9.0000000000000602.


References
1.
Pedroza M, To S, Smith J, Agarwal S . Cadherin-11 contributes to liver fibrosis induced by carbon tetrachloride. PLoS One. 2019; 14(7):e0218971. PMC: 6608953. DOI: 10.1371/journal.pone.0218971. View

2.
Triantafyllou E, Woollard K, McPhail M, Antoniades C, Possamai L . The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure. Front Immunol. 2019; 9:2948. PMC: 6302023. DOI: 10.3389/fimmu.2018.02948. View

3.
Heymann F, Hammerich L, Storch D, Bartneck M, Huss S, Russeler V . Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology. 2011; 55(3):898-909. PMC: 4533854. DOI: 10.1002/hep.24764. View

4.
Roszer T . Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015; 2015:816460. PMC: 4452191. DOI: 10.1155/2015/816460. View

5.
Gao B, Bataller R . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5):1572-85. PMC: 3214974. DOI: 10.1053/j.gastro.2011.09.002. View